CariGenetics Partners with Concr to Drive Global Precision Medicine Using Caribbean Genetic Data

Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXfYl_Wec3tMXCh1g3zl8r8f_y8KPdVO6ChZSgcs6X0Q0ky1nqYfXMFg19_AsnrJbv65T0j0hTl2KlL3W8TItHDateQUmsBvJKkBr6qZP784AzqdyOZKmB8_uxgcBWzu1TtXXtzeCQ?key=GuCe-UsjSubPTgXIT71MkPAz

Hamilton, Bermuda - Concr, a deeptech company dedicated to enabling precision medicine and improving drug development using predictive analytics and artificial intelligence (AI), has announced its partnership with CariGenetics. Through this collaboration, Concr and CariGenetics will expand use of vital genetic and molecular data on Triple Negative Breast Cancer (TNBC) from the Caribbean region, filling a critical gap in diversity for global healthcare and the pharmaceutical industry.

In a statement, Concr emphasized the importance of the high-quality and diverse datasets developed by CariGenetics, stressing the need for comprehensive data to train algorithms that accurately reflect the global population. "Including diverse data, especially data representing people who've historically been overlooked in research, is not just about making AI fairer, it's essential to broaden our understanding of biology and science," said Concr's CEO Dr Irina Babina. "We are thrilled to partner with CariGenetics who are so uniquely positioned to address this critical need by generating data that supports more accurate, personalized therapy across diverse populations. While historical data brings valuable insights, deliberate prospective data collections like those at CariGenetics is how we advance the field."

By linking clinical, genetic, and molecular TNBC data from the Caribbean-a region historically underrepresented in genomics and AI research-CariGenetics is addressing disparities in healthcare research and innovation. Concr also highlighted the increasing demand among pharmaceutical companies for robust and inclusive AI models to drive drug discovery and development. Many organizations are appointing AI and data specialists to leadership roles, reflecting the growing need for high-quality, diverse datasets like those provided by CariGenetics.

Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXcHqOLOdqyL5yljiYrd4_bJObnrgR8ky-n_mvHsm6FmP-EnthjqyusKUfVteMKNOlPwQDlZM2oo6xf_HaKmzNv1gNTAwDlleqV2uvcG_kRs3oCx2OKFuuSgCU2-jl_WmY3Ojkhk?key=GuCe-UsjSubPTgXIT71MkPAz

Photo Courtesy: The Brand Development Group / Concr

Dr. Carika Weldon, CEO of CariGenetics, commented on the collaboration: "We are thrilled to partner with Concr to ensure the Caribbean's unique genetic data informs AI-driven advances in healthcare. Our mission is to bring the region to the forefront of precision medicine, so that the next generation of treatments is both more inclusive and effective for diverse populations."

Through this partnership, CariGenetics' work will directly support the creation of AI models that enhance patient care for underrepresented populations. The collaboration is positioned to not only propel the future of AI-driven precision medicine but also to provide Caribbean communities with access to the latest advancements in personalised healthcare.

For more information about CariGenetics and its partnership with Concr, please visit http://www.carigenetics.com.

For media inquiries contact: Concr - Emre Misirlioglu; info@concr.co

About CariGenetics

CariGenetics is the world's first research company focused on understanding the unique genetics of Caribbean people. CariGenetics is dedicated to advancing personalized medicine and improving healthcare outcomes for the Caribbean community through groundbreaking genetic studies and innovative research initiatives that embrace the region's distinct heritage.

About Concr

Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics.

Our Farr-Sight Registered platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare.

Concr's investors include the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom. The company has also received a grant from Innovate UK to trial Concr's technology for improving treatment decision-making in clinics. The company's HQ is in London, England, with a wholly owned subsidiary in Brisbane, Australia.
Media Contact
Company Name: The Brand Development Group
Contact Person: Jodi Covington
Email: Send Email [http://www.universalpressrelease.com/?pr=carigenetics-partners-with-concr-to-drive-global-precision-medicine-using-caribbean-genetic-data]
Phone: 4044573589
Country: United States
Website: http://www.branddevgroup.com



This release was published on openPR.